SmithKline's Data Challenge
SmithKline's access to databases at Diversified, United HealthCare and SB Clinical Labs gives it an enormous potential advantage in terms of creating an information-based pharmaceutical care business. It wants to put together all this information, creating previously un-doable disease management programs to reduce customers' costs dramatically, raise its own margins and keep competitors at bay. But the problems in normalizing data between different organizations, cleaning incorrect data, and reconfiguring computer systems will make this a long-term process.
You may also be interested in...
AdvaMed Accell executive director Ashley Wittorf spoke in support of a proposed US House bill that would give financial help to small companies making products to address COVID-19.
Risdiplam’s efficacy across two clinical trials and oral dosing made it a credible threat before its US FDA approval, but its weight-based pricing falls below Biogen’s Spinraza and Novartis’s Zolgensma.
A pilot that used RFID tags with 2D barcodes was touted as more effective than using 2D barcodes alone in tracking drugs through the supply chain.